Skip to Main Content

An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Conditions

Leukemia, other

Phase II

What is the purpose of this trial?

This is a Bayesian adaptive dose-finding study in patients with primary or secondary myelofibrosis:

  1. who have failed therapy with ruxolitinib on the basis of intolerance or loss of efficacy,
  2. highly symptomatic (DIPSS risk score of Intermediate-1, Intermediate-2 or High Risk, and MPN-SAF TSS 2.0 of ≥10),
  3. and have splenomegaly (assessed by physical examination).
  • Trial with
    CTI BioPharma Corp.
  • Start Date
    09/22/2020
  • End Date
    07/31/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/15/2021
  • Study HIC
    #2000021484